Novo Nordisk says compounder falsely advertised weight-loss drugs as FDA-approved
MLex Summary: Novo Nordisk, which markets its FDA-approved semaglutide products under the trademarks Ozempic®, Wegovy®, and Rybelsus®, is accusing Solace Integrative Mental Health of marketing compounded drugs for weight loss that...To view the full article, register now.
Already a subscriber? Click here to view full article